1. The Сoncept of Mobile Diagnostic Device by
МetaScan
Cambridge - Snezhinsk

2. Introduction.
Our team was formed during this competition as a joint venture between
(Snezhinsk, Russia) (Cambridge, Great Britain)
portable
new monitor of new
technology prostate biomarkers
pathology
МетаСкан

3. Genomics, proteomics, metabolomics…
МетаСкан

4. Metabolomics – methods and instruments.
Total Analytical System (TAS) Selective Sensors
FreeStyle
HPLC-MS
DFS
HPLC-ECD
Micro Total Analytical CoulArray System
System (μTAS)
i-STAT
МетаСкан

5. Portable solutions.
Selective Sensors i-STAT
FreeStyle
~ $ 40 ~ $ 12 000
year 1972 year 1995 year 2000
First portable analyser measuring
First portable Modern glucose
in 10 min blood gases,
glucose meter meter
electrolytes, some protein
markers, several metabolites and
haematocrit.
МетаСкан

6. Product Overview.
Gadget for home use for
indication of a problem
CoulArray System
disposable cratridge
Medical diagnostic device for precise diagnostics
МетаСкан

7. IT solution structure.

8. Product Overview.
Price estimation for small scale production
• gadget - 400-500 USD;
•disposable cartridge-sensor – 10-15 USD.
МетаСкан

9. Competitive advantages.
• High diagnostic accuracy
• Affordability, low cost
• Non-invasive
• Easy-to-use
• Immediate result
• Proprietary biomarkers
МетаСкан

10. Business model.
gadget sales
cartridge sales
license sales to large producers
sales to professional medical market
МетаСкан

11. Risk Management.
Achieving high specificity and Use of the combination of several markers
accuracy of the test Large clinical trials for high statistical power
CE certification (in Europe) as home use
Certification
gadget
Russian patent for technology is present
IP protection
Further patenting of the device and markers
МетаСкан

12. Team - Oncometrics
Dr Mikhail Lomonosov, Managing Director, over
12 years of experience in Cancer Biomarkers and
Molecular Therapies. Cambridge University.
Irina Soltamova Solovyev, Director, over 15 years of experience in
financial consulting and auditing. Founder and Director of group of
companies with international clientele.
Dr Dmitry Soloviev, Science Director, over 20 years of experience in
development, synthesis and production of diagnostic
radiopharmaceuticals for cancer pre-clinical and clinical trials. Cancer
Research UK
МетаСкан

13. Team-ECOSCAN
1
Sergey Sokolkov, PhD,
68
67 100000 2 3
66 4
65 5
64 6
Nikolai Zababahin
63 7
62 10000 8
61 9
60 10
director of “EcoScan”
59 1000 11
58 12
construction engineer
57 13
100
56 14
55 15
54 10 16
53 17
52 1 18
51 19
50 20
49 21
48 22
47 23
46 24
45 25
44 26
43 27
42 28
41 29
40 30
Aleksandr Karzhenkov
39 31
38 37 33 32
36 34
35
system integrator Stanislav Liapin
leading developer
Aleksei Chupurnov
leading programmer
1,2
1,0
0,8
0,6
0,4
Q [rel. unit]
0,2
0,0
0,0 50,0 100,0 150,0 200,0 250,0 300,0 350,0
-0,2
-0,4
МетаСкан
-0,6
-0,8
-1,0
t [sec.]

14. Partners.
Partners for development of radiation modified high capillary density
polymer material
Laboratory ENU, Astana, Kazakhstan
Affiliated centre of the Institute of
Nuclear Physics, Astana, Kazakhstan
МетаСкан

15. Road Map.
Phase Tasks Investments Time
1. Technical development 4.9 млн. руб. 1 year
2. Clinical proof of concept, phase 1 clinical trials 2.6 млн. руб. 0,5 year
End of Skolkovo’s grant. Result – concept is proved. Next – bringing in investor
3. Phase 2 clinical trials 20 млн. руб. 1 year
Ready for market
4. Licensing, preparation for manufacturing 10 млн. руб. 1 year
5. Manufacturing and marketing 40 млн. руб. 1,5 year
МетаСкан

16. Thank you!
Contacts:
Соколков Сергей (Снежинск) – ssokolkov@yandex.ru, м.б. +79048186906
Михаил Ломоносов (Кембридж) - mikhail.lomonosov@gmail.com,
+44(7855862351)
МетаСкан